PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25181481-6 2014 The nonselective protein tyrosine kinase inhibitors genistein and AG490 as well as the selective extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitors PD98059 and SL327 suppressed the mGluR1-mediated current responses. SL 327 171-176 mitogen-activated protein kinase 3 Mus musculus 97-138 25181481-6 2014 The nonselective protein tyrosine kinase inhibitors genistein and AG490 as well as the selective extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitors PD98059 and SL327 suppressed the mGluR1-mediated current responses. SL 327 171-176 mitogen-activated protein kinase 3 Mus musculus 140-146 16504549-5 2006 In the present study, in order to investigate the involvement of MAPKs in memory reconsolidation processes we administered immediately after retrieval, different doses of SL327 (an inhibitor of MEK, a kinase that activates both ERK1 and ERK2) both in C57BL/6 (C57) mice and ERK1 mutant mice tested in a fear conditioning task. SL 327 171-176 mitogen-activated protein kinase 3 Mus musculus 228-232 21394501-7 2012 Pharmacological inhibition of ERK1/2 by PD98059 and SL327 restored the anti-invasion effects of mTOR inhibition in vitro. SL 327 52-57 mitogen-activated protein kinase 3 Mus musculus 30-36 19402951-3 2009 The intervention group received the ERK1/2 signaling pathway inhibitor SL327 before the pilocarpine injection. SL 327 71-76 mitogen-activated protein kinase 3 Mus musculus 36-42 17907844-4 2007 To determine whether ERK 1/2 plays a role in this enhancement, a dose of SL327 (a selective, systemic ERK 1/2 inhibitor) that is subthreshold for inhibiting contextual fear conditioning was coadministered with nicotine prior to training, testing, or both training and testing of contextual fear conditioning in C57BL/6 mice. SL 327 73-78 mitogen-activated protein kinase 3 Mus musculus 102-109 17596448-7 2007 Thus, pharmacological inactivation of ERK1/2 achieved using SL327 (alpha-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile), an inhibitor of the mitogen-activated kinase/ERK kinase, MEK, during chronic L-DOPA treatment counteracts the induction dyskinesia. SL 327 60-65 mitogen-activated protein kinase 3 Mus musculus 38-44 17596448-7 2007 Thus, pharmacological inactivation of ERK1/2 achieved using SL327 (alpha-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile), an inhibitor of the mitogen-activated kinase/ERK kinase, MEK, during chronic L-DOPA treatment counteracts the induction dyskinesia. SL 327 67-149 mitogen-activated protein kinase 3 Mus musculus 38-44 23012487-6 2012 Inhibition of ERK1/2 activation 2 hr after AA injection by subcutaneous (sc) injection of the mitogen-activating extracellular kinase (MEK) inhibitor, SL327, had no effect on the nocifensive responses, but did attenuate anxiety-like behavior, as determined by elevated plus-maze and open-field testing results. SL 327 151-156 mitogen-activated protein kinase 3 Mus musculus 14-20 20739576-9 2010 Additionally, systemic MEK inhibition with SL327 (alpha-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile) attenuated formalin-induced spontaneous behaviors similarly in wild-type and ERK1 KO mice, indicating that unrelated signaling pathways do not functionally compensate for the loss of ERK1. SL 327 43-48 mitogen-activated protein kinase 3 Mus musculus 211-215 20739576-9 2010 Additionally, systemic MEK inhibition with SL327 (alpha-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile) attenuated formalin-induced spontaneous behaviors similarly in wild-type and ERK1 KO mice, indicating that unrelated signaling pathways do not functionally compensate for the loss of ERK1. SL 327 43-48 mitogen-activated protein kinase 3 Mus musculus 317-321 16504549-5 2006 In the present study, in order to investigate the involvement of MAPKs in memory reconsolidation processes we administered immediately after retrieval, different doses of SL327 (an inhibitor of MEK, a kinase that activates both ERK1 and ERK2) both in C57BL/6 (C57) mice and ERK1 mutant mice tested in a fear conditioning task. SL 327 171-176 mitogen-activated protein kinase 3 Mus musculus 274-278 16504549-7 2006 Moreover, SL327 administration impaired memory reconsolidation also in ERK1 mutant mice. SL 327 10-15 mitogen-activated protein kinase 3 Mus musculus 71-75 15305880-3 2004 Moreover, the ability of haloperidol and eticlopride to stimulate phosphorylation at both seryl residues is prevented by treatment with SL327, a compound that blocks activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2). SL 327 136-141 mitogen-activated protein kinase 3 Mus musculus 236-242 32931814-7 2020 Next, the blockade of ERK1/2 pathway by SL-327, a selective MEK1/2 inhibitor, was checked for anxiolytic action. SL 327 40-46 mitogen-activated protein kinase 3 Mus musculus 22-28 32931814-11 2020 Co-administration of subeffective doses of SL-327 and diazepam induces anxiolysis, which is CaMKII-independent and correlates to selectively decreased phosphoactive ERK1/2 in the hippocampus. SL 327 43-49 mitogen-activated protein kinase 3 Mus musculus 165-171 30003929-10 2019 SL-327 (a MEK inhibitor) augmented KET sleep, further indicating the relevance of reduced p-ERK1/2 in KET-induced hypnosis. SL 327 0-6 mitogen-activated protein kinase 3 Mus musculus 92-98 28356400-4 2017 The functional role of the ERK1/2 pathway activation during sexual behaviour was explored with the administration of a MEK inhibitor, SL-327 (30 mg/kg, i.p. SL 327 134-140 mitogen-activated protein kinase 3 Mus musculus 27-33 30104581-7 2018 Systemic injection of SL327 (an inhibitor of MEK1/2 that also blocks its downstream signal ERK1/2) prior to RS rescued the working memory impairments and the increased p-ERK1/2 while normalizing the expression of Egr1. SL 327 22-27 mitogen-activated protein kinase 3 Mus musculus 91-97 30104581-7 2018 Systemic injection of SL327 (an inhibitor of MEK1/2 that also blocks its downstream signal ERK1/2) prior to RS rescued the working memory impairments and the increased p-ERK1/2 while normalizing the expression of Egr1. SL 327 22-27 mitogen-activated protein kinase 3 Mus musculus 170-176